ArticleJournal of neural transmission (Vienna, Austria : 1996)2026
Protective effect of formononetin in chronic unpredictable stress (CUS) linked to parkinson disease.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Formononetin [FMN] belongs to the member of class 7-hydroxyisoflavones possesses anti-oxidant and anti-inflammatory activity. However, its efficacy in chronic unpredictable stress (CUS) associated with Parkinson disease (PD) is not evaluated. In a current study the effect of FMN on CUS associated with PD was screened to examine efficacy using different behavioral, biochemical and immuno-histochemical evaluation. During the study, CUS associated with PD was induced in mice by administering rotenone followed by exposure to different mild stressors. Animals showing CUS linked to PD were included in the study and treated daily with FMN (5, 10 & 20 mg/kg) by intraperitoneal route. After the treatment, animals evaluated for behavioral, biochemical parameters and immunohistochemistry analysis. Treatment with FMN was effective in alleviating core symptoms of chronic stress linked to PD and improved cognitive function, gait abnormality and impairment in co-ordination of CUS + ROT model. FMN showed dose dependent reduction in IL- 1β, TNF- α, IL- 6 concentration. FMN increasing the levels of dopamine, norepinephrine and serotonin. Immunohistochemical study revealed that the expression of α-synuclein reduced which helps to improve CUS linked to Parkinson's. Furthermore, expression of BDNF and BCL-2 found to be improved after FMN treatment and helps in elevation of dopamine levels thereby surviving neuronal system. Study findings revealed that formononetin is effective in the treatment of chronic unpredictable stress linked to Parkinson's, however further clinical investigation is required to evaluate its effect in human.
Indexed as
Identifiers
40377696What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.